https://www.selleckchem.com/products/loxo-195.html
In vivo, atrase B-treated rats showed a significant reduction in serum complement activity; markedly prolonged PT, APTT, and TT; and a decreased plasma level of fibrinogen. When compared to PBS treatment evaluated at study endpoint, atrase B treatment significantly delayed xenograft rejection and attenuated pathologic damage, the formation of platelet microthrombi, and the deposition of fibrin and C5b-9. Conclusions The dual activities of anti-complement and anti-coagulation make atrase B a potential adjuvant therapeutic drug for use i
Like
Comment
Share
